-+ 0.00%
-+ 0.00%
-+ 0.00%

Tianjin Pharmaceutical (600488.SH): Betamethasone API obtains FDA DMF FA Letter

Zhitongcaijing·11/20/2026 07:57:16
Listen to the news

Zhitong Finance App News, Tianjin Pharmaceutical (600488.SH) issued an announcement. Recently, the company received a DMF First Approval Letter (“DMF FA Letter”) issued by the US Food and Drug Administration (“FDA”), indicating that the FDA has completed a scientific review of the DMF file for the company's betamethasone API. Betamethasone is suitable for hyporenin hypoaldosterone syndrome and postural hypotension and allergic and autoimmune inflammatory diseases caused by autonomic neuropathy. It is now mostly used for active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, acute leukemia, etc., and is also used for comprehensive treatment of certain infections. The API has passed the technical review this time, which will have a positive impact on the company's expansion of the US market and improved performance.